Print

HPTN 076

HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)

Trial Details:

II Ongoing
October 01, 2014
Rilpivirine
Rilpivirine
USA, South Africa 132
NCT02165202